Composition for preventing or treating benign tumor

A method for treating a benign tumor expressing WT1 selected from the group consisting of familial adenomatous polyposis, non-hereditary colorectal adenoma, intraductal papillary mucinous neoplasm, meningioma, schwannoma, epithelial adenoma of an organ, papilloma, non-epithelial myoma, lipoma, and chondroma in a subject, the method comprising:

• administering to the subject an effective amount of a nucleic acid molecule encoding a peptide selected from the group consisting of
• RMFPNAPYL of SEQ ID NO:
• 2,
• RYFPNAPYL of SEQ ID NO:
• 46,
• YMFPNAPYL of SEQ ID NO:
• 14,
• CYTWNQMNL of SEQ ID NO:
• 45,
• CMTWNQMNL of SEQ ID NO:
• 3,
• C-CYTWNQMNL of SEQ ID NO:
• 47 wherein C-C shown in the formula means that the C residues are linked together by a disulfide bond, and
• C-CMTWNQMNL of SEQ ID NO:
• 48 wherein C-C shown in the formula means that the C residues are linked together by a disulfide bond.

A method, comprising:

• culturing peripheral blood mononuclear cells from a subject in need of treatment for a benign tumor selected from the group consisting of familial adenomatous polyposis, non-hereditary colorectal adenoma, intraductal papillary mucinous neoplasm, meningioma, schwannoma, epithelial adenoma of an organ, papilloma, non-epithelial myoma, lipoma, and chondroma in the presence of a peptide;
• and
• inducing WT1-specific CTLs and/or WT1-specific helper T cells from the peripheral blood mononuclear cells,
• wherein the peptide is selected from the group consisting of
• RMFPNAPYL of SEQ ID NO:
• 2,
• RYFPNAPYL of SEQ ID NO:
• 46,
• YMFPNAPYL of SEQ ID NO:
• 14,
• CYTWNOMNL of SEQ ID NO:
• 45,
• CMTWNQMNL of SEQ ID NO:
• 3,
• C-CYTWNQMNL of SEQ ID NO:
• 47 wherein C-C shown in the formula means that the C residues are linked together by a disulfide bond, and
• C-CMTWNQMNL of SEQ ID NO:
• 48 wherein C-C shown in the formula means that the C residues are linked together by a disulfide bond.

A method, comprising:

• culturing immature dendritic cells from a subject in need of treatment for a benign tumor selected from the group consisting of familial adenomatous polyposis, non-hereditary colorectal adenoma, intraductal papillary mucinous neoplasm, meningioma, schwannoma, epithelial adenoma of an organ, papilloma, non-epithelial myoma, lipoma, and chondroma in the presence of a peptide;
• and
• inducing WT1-presenting dendritic cells,
• wherein the peptide is selected from the group consisting of
• RMFPNAPYL of SEQ ID NO:
• 2,
• RYFPNAPYL of SEQ ID NO:
• 46,
• YMFPNAPYL of SEQ ID NO:
• 14,
• CYTWNOMNL of SEQ ID NO:
• 45,
• CMTWNQMNL of SEQ ID NO:
• 3,
• C-CYTWNQMNL of SEQ ID NO:
• 47 wherein C-C shown in the formula means that the C residues are linked together by a disulfide bond, and
• C-CMTWNQMNL of SEQ ID NO:
• 48 wherein C-C shown in the formula means that the C residues are linked together by a disulfide bond.

A method, comprising:

• culturing peripheral blood mononuclear cells from a subject in need of treatment for a benign tumor selected from the group consisting of familial adenomatous polyposis, non-hereditary colorectal adenoma, intraductal papillary mucinous neoplasm, meningioma, schwannoma, epithelial adenoma of an organ, papilloma, non-epithelial myoma, lipoma, and chondroma in the presence of a conjugate of formulas (2) or (3);
• and
• inducing WT1-specific CTLs and/or WT1-specific helper T cells from the peripheral blood mononuclear cells,
• wherein the conjugate of the formula (2) is
• and the conjugate of the formula (3) is
• wherein C-C shown in the formulas (2) and (3) means that the C residues are linked together by a disulfide bond.

A method, comprising:

• culturing immature dendritic cells from a subject in need of treatment for a benign tumor selected from the group consisting of familial adenomatous polyposis, non-hereditary colorectal adenoma, intraductal papillary mucinous neoplasm, meningioma, schwannoma, epithelial adenoma of an organ, papilloma, non-epithelial myoma, lipoma, and chondroma in the presence of a conjugate of formulas (2) or (3);
• and
• inducing WT1-presenting dendritic cells,
• wherein the conjugate of the formula (2) is
• and the conjugate of the formula (3) is
• wherein C-C shown in the formulas (2) and (3) means that the C residues are linked together by a disulfide bond.

A method, comprising:

• introducing a nucleic acid molecule, which encodes a peptide into peripheral blood mononuclear cells from a subject in need of treatment for a benign tumor selected from the group consisting of familial adenomatous polyposis, non-hereditary colorectal adenoma, intraductal papillary mucinous neoplasm, meningioma, schwannoma, epithelial adenoma of an organ, papilloma, non-epithelial myoma, lipoma, and chondroma;
• and
• inducing WT1-specific CTLs and/or WT1-specific helper T cells from the peripheral blood mononuclear cells,
• wherein the peptide is selected from the group consisting of
• RMFPNAPYL of SEQ ID NO:
• 2,
• RYFPNAPYL of SEQ ID NO:
• 46,
• YMFPNAPYL of SEQ ID NO:
• 14,
• CYTWNQMNL of SEQ ID NO:
• 45,
• CMTWNQMNL of SEQ ID NO:
• 3,
• C-CYTWNQMNL of SEQ ID NO:
• 47 wherein C-C shown in the formula means that the C residues are linked together by a disulfide bond, and
• C-CMTWNQMNL of SEQ ID NO:
• 48 wherein C-C shown in the formula means that the C residues are linked together by a disulfide bond.

A method, comprising:

• introducing a nucleic acid molecule, which encodes a conjugate of formulas (2) or (3) into peripheral blood mononuclear cells from a subject in need of treatment for a benign tumor selected from the group consisting of familial adenomatous polyposis, non-hereditary colorectal adenoma, intraductal papillary mucinous neoplasm, meningioma, schwannoma, epithelial adenoma of an organ, papilloma, non-epithelial myoma, lipoma, and chondroma;
• and
• inducing WT1-specific CTLs and/or WT1-specific helper T cells from the peripheral blood mononuclear cells,
• wherein the conjugate of the formula (2) is
• and the conjugate of the formula (3) is
• wherein C-C shown in the formulas (2) and (3) means that the C residues are linked together by a disulfide bond.

A method, comprising:

• introducing a nucleic acid molecule, which encodes a peptide into immature dendritic cells from a subject in need of treatment for a benign tumor selected from the group consisting of familial adenomatous polyposis, non-hereditary colorectal adenoma, intraductal papillary mucinous neoplasm, meningioma, schwannoma, epithelial adenoma of an organ, papilloma, non-epithelial myoma, lipoma, and chondroma;
• and
• inducing WT1-presenting dendritic cells,
• wherein the peptide is selected from the group consisting of
• RMFPNAPYL of SEQ ID NO:
• 2,
• RYFPNAPYL of SEQ ID NO:
• 46,
• YMFPNAPYL of SEQ ID NO:
• 14,
• CYTWNQMNL of SEQ ID NO:
• 45,
• CMTWNQMNL of SEQ ID NO:
• 3,
• C-CYTWNQMNL of SEQ ID NO:
• 47 wherein C-C shown in the formula means that the C residues are linked together by a disulfide bond, and
• C-CMTWNQMNL of SEQ ID NO:
• 48 wherein C-C shown in the formula means that the C residues are linked together by a disulfide bond.

A method, comprising:

• introducing a nucleic acid molecule, which encodes a conjugate of formulas (2) or (3) into immature dendritic cells from a subject in need of treatment for a benign tumor selected from the group consisting of familial adenomatous polyposis, non-hereditary colorectal adenoma, intraductal papillary mucinous neoplasm, meningioma, schwannoma, epithelial adenoma of an organ, papilloma, non-epithelial myoma, lipoma, and chondroma;
• and
• inducing WT1-presenting dendritic cells,
• wherein the conjugate of the formula (2) is
• and the conjugate of the formula (3) is
• wherein C-C shown in the formulas (2) and (3) means that the C residues are linked together by a disulfide bond.